Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors

被引:96
|
作者
Sunderkoetter, C. [1 ]
Herrgott, I. [1 ]
Brueckner, C. [2 ]
Moinzadeh, P. [3 ]
Pfeiffer, C. [4 ]
Gerss, J. [5 ]
Hunzelmann, N. [3 ]
Boehm, M. [1 ]
Krieg, T. [3 ]
Mueller-Ladner, U. [6 ]
Genth, E. [7 ]
Schulze-Lohoff, E. [8 ]
Meurer, M. [4 ]
Melchers, I. [9 ]
Riemekasten, G. [2 ]
机构
[1] Univ Munster, Dept Dermatol, D-48149 Munster, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Univ Cologne, Dept Dermatol & Venerol, Cologne, Germany
[4] Dresden Univ Hosp, Dept Dermatol, Dresden, Germany
[5] Univ Munster, Coordinating Ctr Clin Trials, Dept Med Informat & Biomath, D-48149 Munster, Germany
[6] Univ Giessen, Kerckhoff Clin, Dept Rheumatol & Clin Immunol, Bad Nauheim, Germany
[7] Univ Aachen, D-5100 Aachen, Germany
[8] Hosp Cologne Merheim, Med Clin 1, Cologne, Germany
[9] Univ Med Ctr Freiburg, Clin Res Unit Rheumatol, Freiburg, Germany
关键词
digital ulcers; German Network; Raynaud's phenomenon; risk factors; systemic sclerosis; RAYNAUDS-PHENOMENON; GERMAN NETWORK; SCLERODERMA TRIALS; ILOPROST TREATMENT; DISEASE; PATHOPHYSIOLOGY; CONSEQUENCES; DERMATOLOGY; MULTICENTER; MANAGEMENT;
D O I
10.1111/j.1365-2133.2008.09004.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Digital ulcers (DU) are a major complication in the course of systemic sclerosis (SSc). In recent years, efficacious, but expensive therapies (e. g. iloprost, sildenafil, bosentan) have been shown to improve healing or to reduce the recurrence of DU. For optimal management it would be useful to identify the risk factors for DU. Such statistical analyses have been rare because they require a high number of patients. Objectives To identify potential risk factors for DU in patients with SSc. Methods We used the registry of the German Network for Systemic Scleroderma and evaluated the data of 1881 patients included by August 2007. We assessed potential risk factors for DU by comparing patients with (24.1%) and without active DU at time of entry (75.9%). Results Multivariate analysis revealed that male sex, presence of pulmonary arterial hypertension (PAH), involvement of the oesophagus, diffuse skin sclerosis (only when PAH was present), anti-Scl70 antibodies, young age at onset of Raynaud's phenomenon (RP), and elevated erythrocyte sedimentation rate (ESR) significantly impacted on the appearance of DU. Certain combinations increased the patients' probability of presenting with DU, with the highest probability (88%) for male patients with early onset of RP, ESR > 30 mm h(-1), anti-Scl70 antibodies and PAH. Patients with DU developed RP, skin sclerosis and organ involvement approximately 2-3 years earlier than patients without DU. Conclusions The results reveal possible risk factors for the occurrence of DU in SSc. As DU are prone to local complications, prophylactic vasoactive treatment for patients presenting with these factors may be justified.
引用
收藏
页码:835 / 843
页数:9
相关论文
共 50 条
  • [21] Geographic variation as a risk factor for digital ulcers in systemic sclerosis patients: a multicentre registry
    Souza, E. J. R.
    Muller, C. S.
    Horimoto, A. M. C.
    Rezende, R. A.
    Guimaraes, I.
    Mariz, H. A.
    Dantas, A. T.
    Da Costa, I. P.
    Del-Rio, A. P. T.
    Sekiyama, J.
    Kahwage, C. B.
    Kayser, C.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2017, 46 (04) : 288 - 295
  • [22] Domain reporting in Systemic Sclerosis-Related Digital Ulcers: An OMERACT Scoping Review
    Hughes, Michael
    Maltez, Nancy
    Brown, Edith
    Hickey, Virginia
    Shea, Beverley
    Pauling, John
    Proudman, Susanna
    Merkel, Peter A.
    Herrick, Ariane L.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023, 61
  • [23] Association between baseline clinical and imaging findings and the development of digital ulcers in patients with systemic sclerosis
    S. Friedrich
    S. Lüders
    A. M. Glimm
    S. G. Werner
    G. Schmittat
    G. R. Burmester
    M. Backhaus
    G. Riemekasten
    S. Ohrndorf
    Arthritis Research & Therapy, 21
  • [24] Efficacy of adjunctive ambrisentan treatment for digital ulcers in patients with systemic sclerosis: a case series study
    Xu, Bei
    Yu, Ye
    Liang, Junyu
    Xu, Guanhua
    Chen, Weiqian
    Lin, Jin
    Hu, Shenjiang
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [25] Bosentan for digital ulcers in patients with systemic sclerosis
    Nagai, Yayoi
    Hasegawa, Michiko
    Hattori, Tomoyasu
    Okada, Etsuko
    Tago, Osamu
    Ishikawa, Osamu
    JOURNAL OF DERMATOLOGY, 2012, 39 (01) : 48 - 51
  • [26] Impaired Fibrinolysis Is Linked With Digital Vasculopathy and Onset of New Digital Ulcers in Systemic Sclerosis
    Colic, Jelena
    Pruner, Iva
    Damjanov, Nemanja
    Pekmezovic, Tatjana
    Sefik-Bukilica, Mirjana
    Antovic, Aleksandra
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (06) : 598 - 606
  • [27] Treatment of digital ulcers in systemic sclerosis: recent developments and future perspectives
    Sagonas, Ioannis
    Daoussis, Dimitrios
    CLINICAL RHEUMATOLOGY, 2023, 42 (10) : 2589 - 2599
  • [28] Patients' unmet needs and treatment preferences concerning digital ulcers in systemic sclerosis
    Bandini, Giulia
    Alunno, Alessia
    Alcacer-Pitarch, Begonya
    Ruaro, Barbara
    Galetti, Ilaria
    El-Aoufy, Khadija
    Pinheiro, Filipe
    Campanaro, Giulia
    Jade, Judith
    Di Donato, Stefanodi
    Muir, Lindsay
    Pignone, Alberto Moggi
    Bellando Randone, Silvia
    Del Galdo, Francesco
    McMahan, Zsuzsanna H.
    Matucci-Cerinic, Marco
    Hughes, Michael
    RHEUMATOLOGY, 2024, : 1277 - 1283
  • [29] Thermographic Abnormalities are Associated with Future Digital Ulcers and Death in Patients with Systemic Sclerosis
    Hughes, Michael
    Wilkinson, Jack
    Moore, Tonia
    Manning, Joanne
    New, Paul
    Dinsdale, Graham
    Murray, Andrea
    Herrick, Ariane L.
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (08) : 1519 - 1522
  • [30] Dynamics of digital ulcers in systemic sclerosis
    Bobeica, Carmen
    Laurentiu Tatu, Alin
    Craescu, Mihaela
    Solovastru, Laura
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (01) : 61 - 67